WHAT IS GAUCHER DISEASE

Gaucher disease is one of the most common lysosomal storage disorders, affecting an estimated 1 in 40,000 to 1 in 100,000 people around the world.[1] It can be diagnosed at any age from infancy to late adulthood. It is an inherited deficiency of the lysosomal enzyme acid-β-glucosidase (glucocerebrosidase, GBA), which results in the accumulation of glucocerebroside within lysosomes of macrophages.[1]

Gaucher disease can be classified into three types, which make a phenotypic continuum ranging from mild to severe nervous symptoms.[2-4] The classic categories of types 1, 2, and 3 have blurred edges along the continuum of the disease.



Adapted from Sidransky E, 2004. *Mol Genet Metab.* 83(1-2):6-15.[3]

ABOUT GAUCHER DISEASE

GAUCHER DISEASE IS COMMONLY MISDIAGNOSED

ROLE OF HEALTHCARE PROFESSIONALS

DIAGNOSING GAUCHER DISEASE

TREATMENT OF GAUCHER DISEASE

CEREZYME® PRESCRIBING INFORMATION

For healthcare professionals only

References

1. Mistry PK, *et al. Am J Hematol* 2011. 86(1):110-115.
2. Charrow J, *et al. Clin Genet* 2007. 71(3):211-215.
3. Sidransky E, *et al. Mol Genet Metab.* 2004. 83(1-2):6-15.
4. Sidransky E, *et al.* Gaucher disease clinical presentation. Updated November

sanofi

sanofi-aventis (Malaysia) Sdn Bhd (334110-P), Unit TB-18-1, Level 18, Tower B, Plaza 33, No. 1 Jalan Kemajuan, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: 03 7651 0800, Fax: 03 7651 0805.

MAT-MY-2201031 12/2022